Effects of sedation on intradermal skin testing in flea-allergic dogs.
Effects of 4 commonly used sedatives on the wheal-and-flare response to histamine and flea antigen were evaluated in 8 flea-allergic Beagles. Skin testing was performed in 12 separate occasions, 3 to 4 days apart. Twelve intradermal injections were given during each skin test: 5 doubling dilutions of histamine phosphate, 6 doubling dilutions of flea antigen, and a phosphate-buffered saline solution (negative control). Of the 12 intradermal skin tests, 8 were control tests performed on nonsedated dogs. The remaining 4 tests were performed on dogs sedated with xylazine, ketamine and valium combination, acepromazine, or oxymorphone. Oxymorphone had the most profound effect on skin test results, significantly (P less than 0.05) decreasing skin responsiveness in 8 of 11 test sites (by objective evaluation) and in 5 of 11 test sites (by subjective evaluation). Xylazine sedation enhanced skin test results in 4 of 11 test sites (by objective evaluation) and in 1 of 11 test sites (by subjective evaluation). In non instance did xylazine significantly decrease skin responsiveness to histamine or flea antigen. Xylazine is the recommended sedative in dogs when sedation is necessary for intradermal skin testing.
Beale
K M
KM
Blanche Saunders Dermatology Laboratory, College of Veterinary Medicine, University of Florida, Gainesville 32610-0126.
Kunkle
G A
GA
Chalker
L
L
Cannon
R
R
D000075:Acepromazine / Q000009:adverse effects; D000818:Animals; D003975:Diazepam / Q000009:adverse effects; D004283:Dog Diseases / Q000175:diagnosis*; D004285:Dogs; D004338:Drug Combinations; D006632:Histamine / Q000276:immunology; D006967:Hypersensitivity / Q000175:diagnosis / Q000662:veterinary*; D006993:Hypnotics and Sedatives / Q000009:adverse effects*; D007428:Intradermal Tests / Q000662:veterinary*; D007649:Ketamine / Q000009:adverse effects; D010111:Oxymorphone / Q000009:adverse effects; D005423:Siphonaptera / Q000276:immunology*; D014991:Xylazine / Q000009:adverse effects
D004338:Drug Combinations; D006993:Hypnotics and Sedatives; D014991:Xylazine; D000075:Acepromazine; D007649:Ketamine; D006632:Histamine; D010111:Oxymorphone; D003975:Diazepam